Drug Delivery through the Blood-Brain Barrier through Use of Vascular Cell Adhesion Molecule 1- Targeted Nanoparticles
Drug Delivery through the Blood-Brain Barrier through Use of Vascular Cell Adhesion Molecule 1- Targeted Nanoparticles
Files
Publication or External Link
Date
2013
Authors
Adnan, Sakib
Borsellino, Regina
He, Alice
Mukherjee, Somdutta
Peng, Victor
Potti, Karthya
Shih, Kelly
Vaitkus, Janina
Wang, Victor
Woo, Rani
Advisor
Aranda-Espinoza, Jose Helim
Citation
DRUM DOI
Abstract
The blood brain barrier (BBB) is a semi-permeable membrane separating the brain
from the bloodstream, preventing many drugs that treat neurological diseases, such as
Alzheimer’s and Parkinson’s, from reaching the brain. Our project aimed to create a
novel drug delivery system targeting the brain during neural inflammation. We
developed a cationic solid lipid nanoparticle (CSLN) complex composed of cationic
nanoparticles, biotin, streptavidin, and anti-vascular cell adhesion molecule-1 (anti-
VCAM-1) antibodies. The anti-VCAM-1 antibody is used to target VCAM-1, a cell
adhesion protein found on the BBB endothelium. VCAM-1 expression is elevated in
the presence of inflammatory molecules, such as tumor necrosis factor-alpha (TNF-
α). Through the use of a simple BBB model, results showed that our novel drug
delivery system experienced some level of success in targeting the brain
inflammation due to increasing TNF-α concentrations. This is promising for drug
delivery research and provides support for VCAM-1 targeting using more robust and
complex BBB models.